Merger
Acelyrin Rebuffs Concentra’s Acquisition Bid, Reaffirms Commitment to Alumis Merger
Acelyrin, Concentra Biosciences, Alumis, Merger, Acquisition offer, Immunology, Biopharmaceuticals, All-stock transaction
BridgeBio Oncology Therapeutics Goes Public via $450M SPAC Merger
BridgeBio, oncology, SPAC merger, Helix Acquisition Corp. II, KRAS inhibitors, cancer pipeline, RAS pathway, PI3K pathway
Concentra’s Surprise Bid Disrupts Acelyrin-Alumis Merger Plans
Concentra Biosciences, Acelyrin, Alumis, merger disruption, unsolicited offer, biopharmaceutical industry, M&A
Ikena Oncology and Inmagene Biopharmaceuticals Announce Merger to Advance Development of Atopic Dermatitis Treatment
Ikena Oncology, Inmagene Biopharmaceuticals, Merger, Atopic Dermatitis, IMG-007, Monoclonal Antibody, OX40, Biopharmaceuticals, Clinical Stage, Private Placement
nChroma Bio Emerges from Chroma Medicine and Nvelop Therapeutics Merger, Secures $75 Million to Advance Genetic Medicines
nChroma Bio, Chroma Medicine, Nvelop Therapeutics, Genetic Medicines, Epigenetic Editing, Non-Viral Delivery, Biotechnology, Merger, Financing
Palleos Healthcare and OCT Global Unite to Form Comprehensive European Contract Research Organization ###
Palleos Healthcare, OCT Global, European CRO, Merger, Clinical Research, Contract Research Organization
Cytokinetics’ Royalty Agreement Dampens Merger and Acquisition Hopes, Say Investors
Cytokinetics, Merger and Acquisition (M&A), Royalty Agreement, Investors, Biotech Industry